A Retrospective Study Assessing the safety and efficacy of Lenvatinib in patients with advanced Hepatocellular Carcinoma of South Korea
Latest Information Update: 27 Feb 2020
Price :
$35 *
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Feb 2020 New trial record
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium